
World stocks down as markets eye US-China talks, Fed decision
World stocks fell slightly on Wednesday while Treasury yields edged down, after news of a forthcoming meeting between top US and Chinese trade officials and ahead of a Federal Reserve monetary policy statement at the end of its two-day meeting.
The dollar index rose against the yen after three days of declines. Safe-haven gold declined after a two-day rally with the Fed expected to keep interest rates unchanged.
US Treasury Secretary Scott Bessent and chief trade negotiator Jamieson Greer are scheduled to meet China's top economic official for talks at the weekend. It could be the first step to agreement after US President Donald Trump ignited a trade war with the world's No 2 economy last month.
Bessent said his sense is the meeting in Switzerland 'will be about de-escalation,' while China sounded more guarded and cited a proverb about actions speaking louder than words.
'It's a move in the right direction. Until you begin talking you can't make any progress,' said Chris Zaccarelli, chief investment officer at Northlight Asset Management. He noted that but 'until an actual framework or deal is announced, the market doesn't know how to digest the talks.' Also muting market moves was the upcoming Fed update. While investors are not expecting a rate change they will closely monitor Chair Jerome Powell's press conference.
'He'll be pressed to give more of an indication on where the Fed is leaning. Are they leaning more towards protecting the job market or are they leaning more towards fighting inflation?' said Zaccarelli.
On Wall Street at 11:01 a.m. the Dow Jones Industrial Average rose 131.77 points, or 0.33%, to 40,963.18, the S&P 500 fell 1.16 points, or 0.01%, to 5,606.14 and the Nasdaq Composite fell 55.37 points, or 0.30%, to 17,636.66.
MSCI's gauge of stocks across the globe fell 0.56 points, or 0.07%, to 841.35. The pan-European STOXX 600 index fell 0.6%.
In currencies, the US dollar rose against the yen while the euro was barely lower as traders awaited the Fed's update and uncertainty over trade negotiations still weighed on sentiment.
The dollar index, which measures the greenback against a basket of currencies including the yen and the euro, fell 0.13% to 99.37.
The euro was down 0.02% at $1.1366. Against the Japanese yen, the dollar strengthened 0.6% to 143.3.
In US Treasuries, the yield on benchmark US 10-year notes fell 3.7 basis points to 4.281%, from 4.318% late on Tuesday while the 30-year bond yield fell 5 basis points to 4.7628%.
The 2-year note yield, which typically moves in step with expectations for Fed interest rate policy, rose 0.8 basis points to 3.797%, from 3.789% late on Tuesday.
In commodity markets, oil prices dipped as investors waited for the outcome of the U.S.-China trade talks.
US crude fell 0.58% to $58.75 a barrel and Brent fell to $61.71 per barrel, down 0.71% on the day.
Gold prices fell due to a firmer dollar and U.S.-China trade talks optimism, as traders awaited the Fed decision.
Agencies
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Web Release
2 hours ago
- Web Release
Central Pattana & Partners Invest THB 1B in ‘Summer Grand Sale 2025' to Boost Tourism and Thailand's Shopping Appeal
Central Pattana plc, Thailand's leading real estate developer and operator of Central shopping centers nationwide, is teaming up with affiliates under Central Group and key partners across both public and private sectors to launch the Summer Grand Sale 2025—the biggest mid-year sale shopping event of the year. With an investment of THB 1 billion, the campaign offers discounts of up to 80% from over 28,000 brands and 12,000 stores across Central shopping centers. It targets a global audience, including short-haul, long-haul, and high-spending international shoppers. The event will run from 30 May to 13 July 2025 at premier locations including centralwOrld, Central Village Outlet, Central Pattaya, Central Marina Outlet, Central Samui, and Central Phuket. This landmark campaign is backed by Thailand's largest retail alliance, including Central Retail, Central Pattana shopping centers, Central Department Store, Robinson Department Store, Central Online (Central App), Supersports, Central Marketing Group (CMG), Tops Food Hall, Tops, Tops Care, GO Wholesale, Power Buy, OfficeMate, B2S, Robinson Lifestyle, Central Restaurants Group, Centara Hotels and Resorts, GO Hotel, Jubilee Diamond, Evolt Technology, Major Cineplex, SF Cinema, and The 1. It is also supported by the Tourism Authority of Thailand and other strategic partners. Central Pattana continues to collaborate closely with the Tourism Authority of Thailand under the Amazing Thailand Grand Sale campaign to establish Thailand as a premier global shopping destination. This campaign aims to highlight Thailand as a destination rich in food, culture, and shopping experiences. The campaign strategically targets quality tourists, including travelers from Middle East, China, Singapore, Hong Kong, Taiwan, and Malaysia, as well as long-haul visitors from Russia, Europe, the US, and Central Asia. Insights reveal diverse shopper preferences: Chinese tourists often seek Thai fashion and popular eateries; Hong Kong and Singaporean travelers gravitate toward craft goods and Thai desserts; Europeans and Americans favor international fashion brands and premium restaurants, while Middle Eastern and Russian tourists are especially drawn to luxury goods. Central Pattana continues to attract high-spending tourists— 'Quality Shoppers'—as demonstrated by growing e-wallet spending in key tourist malls such as Central Phuket, Central Chiangmai, Central Pattaya, and centralwOrld. This sustained growth reflects the success of its strategic efforts to drive premium tourism. Exclusive Offers for International Visitors: During Summer Grand Sale 2025, international tourists can enjoy exclusive promotions by signing up for The 1 Tourist membership. Members receive a free Tourist Welcome Package with discounts of up to 40%* at participating brands across all Central shopping centers in Thailand. Shoppers who spend THB 6,000* (or THB 5,000* for Klook customers) will receive a complimentary Good Goods Tote Bag valued at THB 690. Offers are available from 30 May to 13 July 2025 at the participating Central locations listed above.


Zawya
3 hours ago
- Zawya
S&P and Moody's upgrade Emaar's credit ratings, citing strong financial performance and robust revenue visibility
-Moody's upgrades Emaar's rating to Baa1 with Stable Outlook Dubai, United Arab Emirates: Emaar Properties PJSC (DFM: EMAAR), one of the world's most valuable and respected real estate development companies, has announced that both S&P Global Ratings and Moody's Ratings have upgraded the company's long-term issuer credit ratings, reinforcing Emaar's position as a financially resilient and strategically agile market leader. S&P Global Ratings upgraded its long-term issuer credit rating to BBB+ from BBB, with a stable outlook, while Moody's upgraded Emaar's long-term issuer rating to Baa1 from Baa2, also with a stable outlook. These upgrades reflect Emaar's robust financial fundamentals, consistent performance, and sound strategic direction. The same S&P and Moody's rating upgrade has been applied to Emaar's senior unsecured debt. Strong Financial Position and Strategic Execution As of March 2025, Emaar reported a revenue backlog of approximately AED 127 billion (US$ 34.6 billion), providing strong revenue and cash flow visibility through 2028. The company's recurring income portfolio continues to expand, supported by disciplined execution, resilient operations, and diversified income streams. S&P's upgrade was driven by Emaar's record-high backlog of AED 110 billion (US$ 29.9 billion) as of December 2024, and healthy presales in the UAE of AED 65.4 billion (US$ 17.8 billion) during 2024, alongside a net cash position, low leverage, and strong adjusted EBITDA margins. Moody's highlighted significant reduction in adjusted debt of Emaar from 2020 to March 2025 and the drop in debt to equity ratio over the same period. Commenting on the announcements, Mohamed Alabbar, Founder of Emaar, said: "We are proud to receive this recognition from both S&P and Moody's, which underscores the strength of our strategy, the quality of our assets, and the discipline we maintain in financial management. These upgrades reflect not only our performance, but also the confidence in Dubai's economy and real estate market. We will continue to pursue sustainable growth, innovation, and value creation for our shareholders and stakeholders alike." Liquidity and Resilience Emaar reported an interest coverage ratio of approximately 24 times for the twelve months ending March 2025 and holds AED 25.4 billion (US$ 6.9 billion) in cash (excluding escrow balances), along with AED 7.4 billion (US$ 2 billion) in undrawn committed credit facilities, providing ample liquidity and financial flexibility. S&P noted that Emaar's strong mall, hospitality, and entertainment operations, in addition to the resilience of its real estate development business, contributed to the rating action. Dubai Mall, for instance, recorded over 111 million visitors in 2024, with overall mall portfolio occupancy of 98.5%, showcasing the strength of Emaar's recurring income-generating assets. Outlook Both agencies issued a stable outlook, reflecting their expectation that Emaar will maintain solid credit metrics, strong liquidity, and continued operational performance. These dual upgrades reinforce Emaar's reputation as a leading player in the global real estate sector, anchored in a dynamic and fast-growing market. For all media queries, please contact: PR@ About Emaar Properties Emaar Properties PJSC, listed on the Dubai Financial Market, is a global property developer and provider of premium lifestyles, with a significant presence in the Middle East, North Africa, and Asia. One of the world's largest real estate companies, Emaar has a land bank of ~1.7 billion sq. ft. in the UAE and key international markets. With a proven track-record in delivery, Emaar has delivered over 120,000 residential units in Dubai and other global markets since 2002. Emaar has strong recurring revenue-generating assets with approx. 1.4 million sq. mtr. of leasing revenue-generating assets and 40 hotels and resorts with over 9,800 keys (includes owned as well as managed hotels). Today, 32 percent of Emaar's revenue is from its shopping malls, hospitality, leisure, entertainment, commercial leasing, and international businesses. Burj Khalifa, a global icon, Dubai Mall, the world's most-visited retail and lifestyle destination, and Dubai Fountain, the world's largest performing fountain, are among Emaar's trophy destinations. Follow Emaar on:


Arabian Post
4 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.